UNSPSC 51373412: Ascorbic acid/hydrocodone/pheniramine/potassium citrate/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373412 Ascorbic acid/hydrocodone/pheniramine/potassium citrate/pyrilamine is a Commodity code that maps poorly to the recent state and local procurement activity posted under it. The two solicitations tagged to this code—one for naloxone and drug deactivation systems, the other for generic multi-source pharmaceuticals and OTC products—do not align with the specific pharmaceutical formulation the code nominally names. The code shows little relevant recent activity for the ascorbic acid/hydrocodone combination specified in its title.

Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with a due date of July 26, 2023 (the source reflects an inconsistent date). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. Neither opportunity targets the specific pharmaceutical formulation indicated by the code's UNSPSC designation, suggesting this code may not be the primary vehicle for state and local procurement of these products or that tagging inconsistencies have obscured the actual scope of buying activity under it.